Iodine

SYNEVIT®'s Synfoline Is a Healthy Pregnancy Precaution

Retrieved on: 
Thursday, February 29, 2024

FORT LAUDERDALE, Fla., Feb. 29, 2024 /PRNewswire/ -- Pregnancy is a demanding activity. A woman's body requires unique quantities and kinds of nutrients when developing a fetus. A lack of nutrition can lead to complications and concerns for a growing child, which is why SYNEVIT® developed its Synfoline pregnancy formula.

Key Points: 
  • A lack of nutrition can lead to complications and concerns for a growing child, which is why SYNEVIT® developed its Synfoline pregnancy formula .
  • Synfoline is a clean, effective prenatal supplement designed to help both mother and child during pregnancy.
  • Neural tube defects are a concern early in pregnancy (including before a woman may realize she is pregnant), which makes Synfoline relevant in the months leading up to conception, as well.
  • "Synfoline allows you to rest in the fact that you're giving your body the nutrients it needs to do just that."

Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®

Retrieved on: 
Thursday, February 22, 2024

GAVRETO generated ~$28M in U.S. net product sales in 2023

Key Points: 
  • GAVRETO generated ~$28M in U.S. net product sales in 2023
    SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has entered into a definitive agreement to acquire the U.S. rights to GAVRETO® (pralsetinib) from Blueprint Medicines Corporation ("Blueprint").
  • "NSCLC is the most common type of lung cancer in the U.S. with RET fusions representing 1-2% of the patient population.
  • Rigel expects to complete the transition of the asset and start recognizing product sales in the third quarter of 2024.
  • Rigel will provide additional details on this transaction at its upcoming quarterly earnings call in early March.

Offshore Greens Unveils Revolutionary Kelp-Based Superfood

Retrieved on: 
Tuesday, February 13, 2024

Offshore Greens' latest offering harnesses the natural abundance of kelp, a superfood known for its high content of iodine, calcium, and antioxidants.

Key Points: 
  • Offshore Greens' latest offering harnesses the natural abundance of kelp, a superfood known for its high content of iodine, calcium, and antioxidants.
  • Sourced from pristine waters, the kelp used in Offshore Greens' product is harvested with eco-friendly methods, ensuring minimal impact on marine ecosystems.
  • The kelp used by Offshore Greens™ has significant human and planetary health benefits.
  • For more information about Offshore Greens and its new kelp-based nutrition product, visit offshoregreens.com .

Summary of opinion: Retsevmo, 25/01/2024 Positive

Retrieved on: 
Sunday, February 4, 2024

On 25 January 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Retsevmo.

Key Points: 
  • On 25 January 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Retsevmo.
  • The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V.
  • The CHMP adopted a new indication to include treatment of adults and adolescents with RET fusion-positive thyroid cancer that is radioactive iodine-refractory.
  • 1 New text in bold

Summary of opinion: Retsevmo, 25/01/2024 Positive

Retrieved on: 
Sunday, February 4, 2024

On 25 January 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Retsevmo.

Key Points: 
  • On 25 January 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Retsevmo.
  • The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V.
  • The CHMP adopted a new indication to include treatment of adults and adolescents with RET fusion-positive thyroid cancer that is radioactive iodine-refractory.
  • 1 New text in bold

This salt alternative could help reduce blood pressure. So why are so few people using it?

Retrieved on: 
Tuesday, January 30, 2024

Excess salt (sodium) increases the risk of high blood pressure so everyone with hypertension is advised to reduce salt in their diet.

Key Points: 
  • Excess salt (sodium) increases the risk of high blood pressure so everyone with hypertension is advised to reduce salt in their diet.
  • It can be used just like regular salt and most people don’t notice any important difference in taste.
  • Switching to potassium-enriched salt is feasible in a way that cutting salt intake is not.

What is potassium-enriched salt?

  • Potassium-enriched salts replace some of the sodium chloride that makes up regular salt with potassium chloride.
  • They’re also called low-sodium salt, potassium salt, heart salt, mineral salt, or sodium-reduced salt.

What is the evidence?


We have strong evidence from a randomised trial of 20,995 people that switching to potassium-enriched salt lowers blood pressure and reduces the risks of stroke, heart attacks and early death. The participants had a history of stroke or were 60 years of age or older and had high blood pressure.
An overview of 21 other studies suggests much of the world’s population could benefit from potassium-enriched salt. The World Health Organisation’s 2023 global report on hypertension highlighted potassium-enriched salt as an “affordable strategy” to reduce blood pressure and prevent cardiovascular events such as strokes.

What should clinical guidelines say?

  • We teamed up with researchers from the United States, Australia, Japan, South Africa and India to review 32 clinical guidelines for managing high blood pressure across the world.
  • While many guidelines recommend increasing dietary potassium intake, and all refer to reducing sodium intake, only two guidelines – the Chinese and European – recommend using potassium-enriched salt.

Why do so few people use it?

  • Few people know a simple switch to potassium-enriched salt can help lower blood pressure and reduce the risk of a stroke and heart disease.
  • Several Australian retailers stock potassium-enriched salt but there is usually only one brand available, and it is often on the bottom shelf or in a special food aisle.


A 2021 review found potassium-enriched salts were marketed in only 47 countries and those were mostly high-income countries. Prices ranged from the same as regular salt to almost 15 times greater. Even though generally more expensive, potassium-enriched salt has the potential to be highly cost effective for disease prevention.

Preventing harm

  • People with serious kidney disease are already advised to avoid regular salt and to avoid foods high in potassium.
  • No harm from potassium-enriched salt has been recorded in any trial done to date, but all studies were done in a clinical setting with specific guidance for people with kidney disease.
  • In some countries, potassium-enriched salt is recommended to the entire community because the potential benefits are so large.

What will happen next?

  • We are working with the taskforce to update Australian hypertension management guidelines, and to promote the new guidelines to health professionals.
  • The next switch to iodised and potassium-enriched salt offers at least the same potential for global health gains.
  • But we need to make it happen in a fraction of the time.
  • Alta Schutte receives funding from the National Health and Medical Research Council of Australia, the Medical Research Future Fund, and NSW Health.
  • She is Company Secretary of the Australian Cardiovascular Alliance, Board Member of Hypertension Australia, and Co-Chair of the National Hypertension Taskforce of Australia.

RocketStar Secures $2 Million in Seed Funding; Acquires Electric Propulsion Company

Retrieved on: 
Wednesday, January 17, 2024

The achievements include securing a $2 million seed investment, acquiring Miles Space, Inc., a space propulsion and spacecraft manufacturer, and announcing a new member to its board of directors, Mr. Mitchel Simpler.

Key Points: 
  • The achievements include securing a $2 million seed investment, acquiring Miles Space, Inc., a space propulsion and spacecraft manufacturer, and announcing a new member to its board of directors, Mr. Mitchel Simpler.
  • RocketStar’s $2 million seed investment will serve to solidify the merger and support operations.
  • This investment also triggered the conversion of a previously issued set of $1.4 million notes to the new Series Seed equity.
  • “The company is proud to have completed this round at a significantly challenging time for such investments,” said RocketStar CEO Chris Craddock.

Summary of opinion: Retsevmo, 25/01/2024 Positive

Retrieved on: 
Monday, January 29, 2024

On 25 January 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Retsevmo.

Key Points: 
  • On 25 January 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Retsevmo.
  • The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V.
  • The CHMP adopted a new indication to include treatment of adults and adolescents with RET fusion-positive thyroid cancer that is radioactive iodine-refractory.
  • 1 New text in bold

NOW® Consumer Survey Unlocks Top Wellness and Health Priorities For 2024

Retrieved on: 
Tuesday, January 9, 2024

BLOOMINGDALE, Ill., Jan. 9, 2024 /PRNewswire/ -- It's no surprise that packed schedules and never-ending to-do lists weigh heavily on people's health, and the need for energy support to get through each day is a priority. In fact, a recent consumer survey commissioned by leading natural products manufacturer NOW® (Suzy.com, October 2023) revealed nearly half of respondents (48%) are looking for supplements to bolster their energy levels.  In addition to increased energy, respondents cited better sleep (35%), improved stress and mood support (30%) and cardiovascular/heart health support (26%) were top wellness priorities and opportunities to find quality supportive supplements.

Key Points: 
  • In addition to increased energy, respondents cited better sleep (35%), improved stress and mood support (30%) and cardiovascular/heart health support (26%) were top wellness priorities and opportunities to find quality supportive supplements.
  • Blatner recommends some NEW supplements from NOW to support consumers' stated wellness priorities.
  • *
    Improved Cardiovascular Function/Heart Health*: NOW® Heart Health Probiotic features Lactobacillus reuteri LRC™, the first heart health probiotic with scientific backing.
  • Do research to confirm any experts promoting the brand on social or other channels are legit and carry meaningful credentials within the health and wellness space.

Novo Integrated Sciences Reports 2023 Fiscal Year Financial Results

Retrieved on: 
Thursday, December 14, 2023

Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2023.

Key Points: 
  • Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints providing services and product innovation, today reported its financial results for the fiscal year ended August 31, 2023.
  • Robert Mattacchione, the Company’s CEO and Board Chairman, stated, “The 2023 fiscal year emphasized maximizing efficiencies pointed toward future cost savings and margin stability.
  • Revenues for the year ended August 31, 2023 were $12,572,019, representing an increase of $834,082, or 7%, from $11,737,937 for the same period in 2022.
  • Net loss attributed to Novo Integrated Sciences for the year ended August 31, 2023 was $13,214,552, representing a decrease of $19,634,663, or 60%, from $32,849,215 for the same period in 2022.